242 related articles for article (PubMed ID: 15905205)
21. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
[TBL] [Abstract][Full Text] [Related]
22. Evidence for common clonal origin of multifocal lung cancers.
Wang X; Wang M; MacLennan GT; Abdul-Karim FW; Eble JN; Jones TD; Olobatuyi F; Eisenberg R; Cummings OW; Zhang S; Lopez-Beltran A; Montironi R; Zheng S; Lin H; Davidson DD; Cheng L
J Natl Cancer Inst; 2009 Apr; 101(8):560-70. PubMed ID: 19351924
[TBL] [Abstract][Full Text] [Related]
23. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
[TBL] [Abstract][Full Text] [Related]
24. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Donati V; Fontanini G
Cancer Invest; 2008 Mar; 26(2):168-72. PubMed ID: 18259947
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-inducible factor-1α polymorphisms are associated with genetic aberrations in lung cancer.
Putra AC; Tanimoto K; Arifin M; Hiyama K
Respirology; 2011 Jul; 16(5):796-802. PubMed ID: 21435097
[TBL] [Abstract][Full Text] [Related]
26. Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China.
Hu N; Huang J; Emmert-Buck MR; Tang ZZ; Roth MJ; Wang C; Dawsey SM; Li G; Li WJ; Wang QH; Han XY; Ding T; Giffen C; Goldstein AM; Taylor PR
Clin Cancer Res; 2001 Apr; 7(4):883-91. PubMed ID: 11309337
[TBL] [Abstract][Full Text] [Related]
27. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
[TBL] [Abstract][Full Text] [Related]
28. [Lung cancer in women: clinical features and factors related to survival].
Sen E; Kaya A; Erol S; Savas I; Gonullu U
Tuberk Toraks; 2008; 56(3):266-74. PubMed ID: 18932027
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
30. TP53 codon 72 polymorphism in oral squamous cell carcinoma.
Drummond SN; De Marco L; Pordeus Ide A; Barbosa AA; Gomez RS
Anticancer Res; 2002; 22(6A):3379-81. PubMed ID: 12530090
[TBL] [Abstract][Full Text] [Related]
31. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer.
Cho S; Kim MJ; Choi YY; Yoo SS; Lee WK; Lee EJ; Jang EJ; Bae EY; Jin G; Jeon HS; Lee SY; Cha SI; Park TI; Kim CH; Park JY
Lung Cancer; 2011 Jul; 73(1):25-31. PubMed ID: 21129811
[TBL] [Abstract][Full Text] [Related]
32. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors.
Bumroongkit K; Rannala B; Traisathit P; Srikummool M; Wongchai Y; Kangwanpong D
Cancer Genet Cytogenet; 2008 Aug; 185(1):20-7. PubMed ID: 18656689
[TBL] [Abstract][Full Text] [Related]
33. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.
Langerød A; Bukholm IR; Bregård A; Lønning PE; Andersen TI; Rognum TO; Meling GI; Lothe RA; Børresen-Dale AL
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1684-8. PubMed ID: 12496062
[TBL] [Abstract][Full Text] [Related]
34. The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients.
Ignaszak-Szczepaniak M; Horst-Sikorska W; Sawicka J; Kaczmarek M; Slomski R
Oncol Rep; 2006 Jul; 16(1):65-71. PubMed ID: 16786124
[TBL] [Abstract][Full Text] [Related]
35. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas.
Lima-Ramos V; Pacheco-Figueiredo L; Costa S; Pardal F; Silva A; Amorim J; Lopes JM; Reis RM
Cancer Genet Cytogenet; 2008 Jan; 180(1):14-9. PubMed ID: 18068527
[TBL] [Abstract][Full Text] [Related]
36. Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer.
Lai KC; Chen WC; Tsai FJ; Li SY; Jeng LB
Hepatogastroenterology; 2005; 52(63):944-8. PubMed ID: 15966238
[TBL] [Abstract][Full Text] [Related]
37. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes.
Papadakis ED; Soulitzis N; Spandidos DA
Br J Cancer; 2002 Oct; 87(9):1013-8. PubMed ID: 12434294
[TBL] [Abstract][Full Text] [Related]
38. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
[TBL] [Abstract][Full Text] [Related]
39. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.
Chen K; Hu Z; Wang LE; Sturgis EM; El-Naggar AK; Zhang W; Wei Q
Carcinogenesis; 2007 Sep; 28(9):2008-12. PubMed ID: 17693666
[TBL] [Abstract][Full Text] [Related]
40. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women.
Bhattacharya P; Sengupta S
Gynecol Oncol; 2005 Oct; 99(1):176-82. PubMed ID: 16054204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
